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Supplementary figure 1a: PRIBA study Profile 
*Analysis inclusion criteria: no additional of non DPP4 glucose lowering therapy, or
discontinuation of >1 co-therapy, between baseline and follow up HbA1c. Self-
reported DPP4 adherence (over 2 weeks prior to HbA1c) ≥75%. Participant not
receiving insulin treatment at study baseline.
 
Commenced DPP4I 
n=305 
On treatment at 3months 
 n=279 
Stopped treatment n=21 
Withdrew prior to follow up visit n=5 
On treatment at 6 months 
 n=254 
Stopped treatment n=8 
Withdrew prior to follow up visit n=17 
Met analysis criteria* at 6 
months n=215 
Met analysis criteria* at 3 
months n=39 
Included in analysis 
 n=254 
 
Supplementary Figure 1b: CPRD study profile 
 
 
 
Supplementary table 1: Associations between markers of insulin resistance and HbA1c response after 6 months, overall 
(Data table for Figure 1) and stratified by sex in a) PRIBA and b) CPRD.  Beta coefficient represents the change in HbA1c 
per standard deviation higher predictor level, a positive coefficient represents an association with reduced response. 
 
a) PRIBA 
  All participants   Males (64%) Females (36%)  
  
Number 
with valid 
baseline data 
Beta coefficient  
(95% CI) 
p-value  
Beta coefficient  
(95% CI) 
p-value 
Beta coefficient  
(95% CI) 
p-value 
HOMA-IR* 242 2.17 (0.62 to 3.72) 0.01   1.69 (-0.26 to 3.64) 0.09 2.87 (0.22 to 5.52) 0.03 
Fasting C-peptide 251 1.67 (0.17 to 3.17) 0.03   1.44 (-0.49 to 3.36) 0.14 1.91 (-0.56 to 4.39) 0.13 
UCPCR** 203 1.65 (-0.07 to 3.37) 0.06  3.35 (1.05 to 5.65) <0.01 -0.56 (-3.16 to 2.04) 0.67 
Fasting Triglycerides 240 2.54 (0.99 to 4.08) <0.01   2.20 (0.35 to 4.05) 0.02 3.31 (0.33 to 6.29) 0.03 
BMI 254 0.96 (-0.54 to 2.46) 0.21   1.23 (-0.89 to 3.35) 0.25 0.29 (-1.98 to 2.56) 0.80 
HDL 243 0.20 (-1.36 to 1.75) 0.81   0.56 (-1.1 to 2.62) 0.60 -0.95 (-3.60 to 1.70) 0.48 
SHBG*** 214 -1.19 (-2.81 to 0.42) 0.15   -1.19 (-3.35 to 0.97) 0.28 -1.23 (-3.79 to 1.33) 0.34 
         
* HOMA2 measured insulin resistance **UCPCR = post meal urine C-peptide Creatinine ratio; ***SHBG = sex-hormone binding globulin 
 
b) CPRD 
   All patients     Males (61%) Females (39%) 
 
Number 
with valid 
baseline data 
Beta coefficient  
(95% CI) 
p-value  
Beta coefficient  
(95% CI) 
p-value 
Beta coefficient  
(95% CI) 
p-value 
BMI 19,430 0.96 (0.78 to 1.15) <0.01   1.04 (0.78 to 1.30) <0.01 0.78 (0.51 to 1.05) <0.01 
Triglycerides 15,404 0.72 (0.50 to 0.93) <0.01   0.82 (0.56 to 1.09) <0.01 0.57 (0.21 to 0.95) <0.01 
HDL 17,058 -0.08 (-0.28 to 0.13) 0.46   -0.22 (-0.49 to 0.05) 0.11 -0.21 (-0.55 to 0.13) 0.22 
 Supplementary table 2: Effect sizes for insulin resistance markers controlling 
for routine clinical characteristics (baseline HBA1c, age at therapy, sex, 
duration of diabetes, eGFR, ethnicity (CPRD only: white, non-white, missing) 
and co-therapy change (PRIBA only, CPRD patients all on unchanged therapy). 
Beta coefficient represents the change in HbA1c at 6 months per standard 
deviation increase in the predictor, a positive coefficient represents an 
association with reduced response. 
a) PRIBA 
 
Number of 
patients 
Beta coefficient (95% CI) p-value 
HOMA-IR 205 2.57 (0.73 to 4.40) <0.01 
Fasting C-peptide 212 2.13 (0.33 to 3.94) 0.02 
Fasting Triglycerides 215 2.34 (0.44 to 4.25) 0.02 
BMI 215 0.67 (-1.15 to 2.50) 0.47 
HDL-c 215 0.09 (-1.69 to 1.86) 0.92 
SHBG 185 -1.04 (-3.00 to 0.91) 0.29 
 
b) CPRD 
  Number of 
patients 
Beta coefficient (95% CI) p-value 
Triglycerides 13,089 0.67 (0.41 to 0.94) <0.01 
BMI 11,683 0.87 (0.61 to 1.12) <0.01 
HDL-c 13,187 -0.11 (-0.35 to 0.14) 0.40 
  
Supplementary table 3: Associations between triglycerides and BMI and 
HbA1c response after 6 months adjusted for baseline HbA1c, fasting glucose 
and co-therapy change in PRIBA. Beta coefficient represents the change in 
HbA1c at 6 months per standard deviation increase in the predictor, a positive 
coefficient represents an association with reduced response.  
  Number of 
patients 
Beta coefficient (95% CI) p-value 
HOMA-IR* 242 1.76 (0.15 to 3.38) 0.03 
Fasting C-peptide 242 1.71 (0.21 to 3.21) 0.03 
UCPCR** 195 1.50 (-0.22 to 3.21) 0.09 
Fasting Triglycerides 231 2.39 (0.84 to 3.94) <0.01 
BMI 244 1.10 (-0.41 to 2.61) 0.15 
HDL-c 233 0.20 (-1.36 to 1.76) 0.80 
SHBG*** 206 -0.90 (-2.53 to 0.73) 0.28 
    
* HOMA2 measured insulin resistance **UCPCR = post meal urine C-peptide Creatinine ratio; 
***SHBG = sex-hormone binding globulin 
 
Supplementary table 4: Associations between routine markers of insulin 
resistance and HbA1c response after 12 months in CPRD. For each predictor 
we ran a separate linear regression model, adjusted for baseline HbA1c. Beta 
coefficient represents the change in HbA1c at 12 months per standard 
deviation increase in the predictor, a positive coefficient represents an 
association with reduced response. 
 
 
 
 
 
Supplementary table 5: Associations between triglycerides and BMI and 
HbA1c response after 6 months in a combined model adjusted for baseline 
HbA1c, and (PRIBA only) co-therapy change in a) PRIBA and b) CPRD. Beta 
coefficient represents the change in HbA1c at 6 months per standard deviation 
increase in the predictor, a positive coefficient represents an association with 
reduced response. 
 a) PRIBA (n=240)  b) CPRD (n=13,543) 
  Beta coefficient 
(95% CI) 
p-value 
Beta coefficient 
(95% CI) 
p-value 
Triglycerides 2.33 (0.71 to 3.94) <0.01 0.56 (0.32 to 0.79) <0.01 
BMI 0.44 (-1.17 to 2.04) 0.59 0.96 (0.73 to 1.18) <0.01 
 
  
  Number of 
patients 
Beta coefficient (95% CI) p-value 
Triglycerides 13,942 0.70 (0.45 to 0.96) <0.01 
BMI 11,206 0.81 (0.59 to 1.04) <0.01 
HDL-c 12,273 -0.32 (-0.57 to -0.08) 0.01 
Supplementary table 6: CPRD hazard ratios for time to glycaemic failure 
(confirmed HbA1c ≥69 mmol/mol (8.5%)) for each predictor in the 
multivariable survival model (n=15,616) 
 Hazard ratio 95% CI p-value 
BMI & Triglyceride subgroup    
BMI<30 & TRGS<2.3 1 (reference)   
BMI≥30 OR TRGS≥2.3 1.17 1.08-1.27 <0.001 
BMI≥30 & TRGS≥2.3 1.28 1.16-1.41 <0.001 
    
Clinical characteristics    
Baseline HbA1c (mmol/mol)* 1.061  1.058-1.064 <0.001 
Age at therapy start (year)* 0.990 0.986-0.994 <0.001 
Duration of diabetes (year)* 1.004 0.997-1.011 0.29 
Female vs male sex 1.075 0.999-1.152 0.04 
eGFR (ml/min/1.3m2)* 1.001 0.999-1.002 0.49 
 
*For continuous variables the hazard ratio represents the change in hazard ratio for a 1 unit increase 
in the predictor. A hazard ratio > 1 indicates a higher value of that variable is associated with shorter 
durability of glycaemic response 
Supplementary Figure 2: Probability of glycemic failure (confirmed HbA1c 
≥8.5%) over 3 years in CPRD in subgroups defined by the presence or absence 
of obesity (BMI>=30 kg/m2) and high triglycerides (TRGs >=2.3mmol/L) - 
Subgroup A: non-obese and normal triglycerides, Subgroup B: non-obese OR 
normal triglycerides, Subgroup C: obese and high triglycerides).   
 
Supplementary table 7: CPRD hazard ratios by BMI & Triglyceride subgroup 
for time to glycaemic failure defined as  
a) Confirmed HbA1c ≥53 (7.5%) (n=15,616)* 
 Hazard ratio 95% CI p-value 
BMI & Triglyceride subgroup    
BMI<30 & TRGS<2.3 1 (reference)   
BMI≥30 OR TRGS≥2.3 1.08 1.02-1.14 0.01 
BMI≥30 & TRGS≥2.3 1.17 1.09-1.25 <0.001 
 
b) Confirmed return to baseline HbA1c level specific to each patient 
(n=15,616)* 
 Hazard ratio 95% CI p-value 
BMI & Triglyceride subgroup    
BMI<30 & TRGS<2.3 1 (reference)   
BMI≥30 OR TRGS≥2.3 1.14 1.05-1.24 0.002 
BMI≥30 & TRGS≥2.3 1.29 1.16-1.42 <0.001 
 
*adjusted for baseline HbA1c, age at therapy, duration of diabetes, sex and eGFR 
  
GLP-1 receptor agonist comparison analysis  
 
Supplementary table 8: GLP-1 receptor agonists - subject baseline 
characteristics  
 
 
 PRIBA 
(n=339) 
CPRD  
(n=4,464) 
Characteristics  
mean (SD) unless stated     
Baseline HbA1c (mmol/mol)  83 (18) 79 (17) 
Baseline HbA1c (%)  9.7 (1.7) 9.4 (1.6) 
Age at therapy start (years)  55 (10) 59 (9) 
Age at diagnosis (years)  47 (10) 51 (8) 
Male sex (%)  56% 58% 
Duration of diabetes (years)  8 (5) 8 (5) 
BMI - median (IQR); mean(SD)  38 (35-44); 40 (8) 37 (34-42); 38 (7) 
Ethnicity (%)    
White  95% 46% 
Non-White  5% 3% 
Missing  0% 51% 
    
Biomarkers 
median (IQR); mean (SD) unless stated     
*=log-transformed    
Triglycerides (mmol/L)  1.9 (1.4-2.6); 2 (1.1)* 2.0 (1.4-2.8); 2.0 (0.5)* 
HDL-c (mmol/L)  1.1 (0.9-1.2); 1.1 (0.3)* 1.1 (0.9-1.2); 1.1 (0.2)* 
LDL-c (mmol/L)  2.2 (1.8-2.8); 2.2 (0.8)* 2.0 (1.6-2.6); 2.0 (0.4)* 
SHBG (nmol/L)  23 (17-36); 24 (14)* NA 
Fasting C-peptide (pmol/L)  1310 (962-1700); 1255 (594)* NA 
HOMA2-%B   49 (32-75); 48 (29)* NA 
HOMA2 IR  4.1 (3.0-5.3); 4.0 (2.1)* NA 
UCPCR nmol/mmol  3.5 (1.9-6.0); 3.1 (2.8)* NA 
eGFR (ml/min/1.3m2)  92 (77-111); 95 (27) 88 (74-102); 88 (22) 
GAD or IA2 positive (%)  1% NA 
    
Therapy    
Number of concomitant therapies at 
therapy start (% of total) 
 
  
0  1% 2% 
1  26% 36% 
2  51% 54% 
3+  22% 8% 
    
GLP-1 type (% of total)    
Dulaglutide  0% 1% 
Exenatide  40% 44% 
Liraglutide  60% 50% 
Lixisenatide  0% 6% 
    
    
 
 
  
Supplementary table 9: GLP-1 receptor agonists - Associations between markers of insulin resistance and HbA1c 
response after 6 months, overall (Data table for Supplementary Figure 2) in a) PRIBA and b) CPRD.  Beta coefficients 
represent the change in HbA1c per standard deviation higher predictor level, a positive coefficient represents an association with 
reduced response. 
 
  PRIBA   CPRD 
  
Number with 
valid baseline 
data 
Beta coefficient 
p-value 
  Number with 
valid baseline 
data 
Beta coefficient 
p-value 
(95% CI)   (95% CI) 
HOMA-IR* 300 0.73 (-0.99 to 2.44) 0.41   NA NA NA 
Fasting C-peptide 333 0.24 (-1.38 to 1.85) 0.78   NA NA NA 
UCPCR** 245 0.45 (-1.37 to 2.26) 0.63   NA NA NA 
Triglycerides 316 0.07 (-1.59 to 1.73) 0.93   2,848 -0.07 (-0.65 to 0.49) 0.80 
BMI 337 0.11 (-1.49 to 1.70) 0.90   4,016 -0.19 (-0.66 to 0.28) 0.43 
HDL 315 1.08 (-0.55 to 2.71) 0.19   3,126 0.01 (-0.53 to 0.55) 0.97 
SHBG*** 317 0.56 (-1.09 to 2.21) 0.50   NA NA NA 
 
 
 
 
  
Supplementary table 10: Mean (95% CI) 6 month baseline HbA1c standardised glycemic response (mmol/mol) for DPP4-
inhibitors and GLP receptor agonists in PRIBA and CPRD. Baseline HbA1c is standardised to the mean PRIBA baseline level 
of 74mmol/mol (8.9%) for all subgroups. 
 DPP4-inhibitors   GLP-1 receptor agonists 
BMI & Triglyceride subgroup PRIBA CPRD   PRIBA CPRD 
BMI<30 & TRGS<2.3 -11.26 (-14.1 to -8.43) -10.28 (-10.72 to -9.85)   -9.64 (-22.75 to 3.48) -9.49 (-12.2 to -6.78) 
BMI≥30 OR TRGS≥2.3 -9.94 (-12.24 to -7.64) -8.79 (-9.12 to -8.47)   -14.7 (-17.11 to -12.29) -10.16 (-10.91 to -9.4) 
BMI≥30 & TRGS≥2.3 -5.23 (-8.62 to -1.84) -7.47 (-7.95 to -6.99)   -13.54 (-16.69 to -10.39) -9.64 (-10.65 to -8.63) 
 
Supplementary Figure 3: GLP-1 receptor agonists - predicted mean absolute HbA1c change from baseline at 6 months in 
a) PRIBA b) CPRD across subgroups defined by the presence or absence of obesity (BMI>=30 kg/m2) and high 
triglycerides (TRGs >=2.3mmol/L) - Subgroup A: non-obese and normal triglycerides, Subgroup B: non-obese OR normal 
triglycerides, Subgroup C: obese and high triglycerides. Baseline HbA1c is standardised to the mean PRIBA baseline level of 
74mmol/mol (8.9%) for all subgroups. Error bars denote 95% confidence intervals. 
  
Supplementary table 10: GLP-1 receptor agonists - CPRD hazard ratios for 
time to glycaemic failure (confirmed HbA1c ≥69 mmol/mol (8.5%) for each 
predictor in the multivariable survival model (n=2,795) 
 
 Hazard ratio 95% CI p-value 
BMI* 1.01 1.00-1.02 0.29 
Triglycerides* 0.99 0.95-1.04 0.80 
Baseline HbA1c (mmol/mol)* 1.05  1.04-1.06 <0.001 
Age at therapy start (year)* 0.98 0.97-0.99 <0.001 
Duration of diabetes (year)* 1.01 0.99-1.03 0.21 
Female vs male sex 0.78 0.67-0.91 0.001 
eGFR (ml/min/1.3m2)* 1.00 1.00-1.00 0.63 
 
*For continuous variables the hazard ratio represents the change in hazard ratio for a 1 unit increase 
in the predictor. A hazard ratio > 1 indicates a higher value of that variable is associated with shorter 
durability of glycaemic response 
 
  
Supplementary table 11: GLP-1 receptor agonists - CPRD hazard ratios 
for time to glycaemic failure (confirmed HbA1c ≥69 mmol/mol (8.5%)) for 
each predictor in the multivariable survival model (n=2,795) 
Hazard ratio 95% CI p-value
BMI & Triglyceride subgroup 
BMI<30 & TRGS<2.3 1 (reference) 
BMI≥30 OR TRGS≥2.3 1.21 0.85-1.73 0.29 
BMI≥30 & TRGS≥2.3 1.13 0.79-1.63 0.50 
Clinical characteristics 
Baseline HbA1c (mmol/mol)* 1.05 1.04-1.06 <0.001 
Age at therapy start (year)* 0.98 0.97-0.99 <0.001 
Duration of diabetes (year)* 1.01 0.99-1.03 0.22 
Female vs male sex 0.79 0.68-0.92 0.002 
eGFR (ml/min/1.3m2)* 1.00 1.00-1.00 0.60 
*For continuous variables the hazard ratio represents the change in hazard ratio for a 1 unit increase
in the predictor. A hazard ratio > 1 indicates a higher value of that variable is associated with shorter
durability of glycaemic response
Supplementary Figure 4: GLP-1 receptor agonists - Probability of glycemic 
failure (confirmed HbA1c ≥8.5%) over 3 years in CPRD in subgroups defined 
by the presence or absence of obesity (BMI>=30 kg/m2) and high triglycerides 
(TRGs >=2.3mmol/L) - Subgroup A: non-obese and normal triglycerides, Subgroup 
B: non-obese OR normal triglycerides, Subgroup C: obese and high triglycerides).   
